7 Things to Know About Retatrutide, a Triple Hormone Receptor Agonist In Development

Few investigational drugs have generated as much clinical and patient interest as retatrutide. This triple agonist peptide has produced phase 3 weight-loss figures that exceed anything previously reported with pharmacotherapy. Patients are increasingly asking about it by name, sometimes after having already obtained “grey-market” versions online.

Retatrutide is not yet FDA approved. But with all the buzz surrounding the medication, it’s worth understanding what the drug is, what the data shows, and how to counsel patients in the meantime. Here are seven things to know.

1. Mechanism of action

Retatrutide is a single molecule that activates three receptors at once:

• glucagon-like peptide-1 (GLP-1)

• glucose-dependent insulinotropic polypeptide (GIP)

• Glucagon

This is what distinguishes it from the current class. Most approved GLP-1 medications act on GLP-1 alone (semaglutide), while tirzepatide adds GIP. Retatrutide is the first agent to add glucagon receptor agonism on top of both.

That glucagon piece is a bigger deal than it sounds. Current incretin mimetics work mostly by curbing intake — slowing gastric emptying and reducing appetite. The glucagon arm adds something new, as it appears to increase energy expenditure and liver fat burning.

In other words, retatrutide is the first injectable medication in this class to work on the output side of the energy equation, not just the intake side. That likely drives both the larger weight-loss numbers and the strong effect on liver fat.

2. Impressive weight loss

Weight loss is the most striking part of the retatrutide story. The pivotal phase 3 trial, TRIUMPH-1, enrolled 2,339 adults with obesity and no history of diabetes. The results – announced by the manufacturer but not yet peer-reviewed – showed average weight loss over 80 weeks of:

• 28.3% (~70 lb) on the 12 mg dose

• 25.9% (~64 lb) on the 9 mg dose

• 19.0% (~47 lb) on the 4 mg dose

• Versus 2.2% on placebo

These are impressive results comparable to weight loss seen with bariatric surgery. In fact, these numbers represent the greatest weight loss ever achieved in a clinical trial for any obesity medication. For context, tirzepatide topped out around 22% and semaglutide around 15% in their pivotal obesity trials. Retatrutide clears the current best results by a wide margin.

3. Greater potency can become a clinical tradeoff

The big weight-loss numbers are the headline. But they also bring clinical issues that are new to this class. In TRIUMPH-1, discontinuations from side effects rose with each dose: 4.1%, 6.9%, and 11.3% at 4 mg, 9 mg, and 12 mg, respectively. This compares to 4.9% drop off on placebo. Some patients also reportedly stopped the medication because they felt they were losing weight too fast.

Such rapid weight loss must be weighed against other effects:

• Muscle and bone: Greater total weight loss can mean a greater loss of lean mass and bone. TRIUMPH-1 didn’t measure body composition directly, and the fat-versus-muscle breakdown is a key detail to watch for in the full publication. Older, frail, and postmenopausal patients may need extra attention to their muscle and bone health.

• Gallstones: Rapid fat loss is a known risk factor for gallstones — in line with the gallbladder warnings across this drug class. A few cases of cholelithiasis did show up in retatrutide phase 2 trial (gallstones in two patients, plus one patient with cholecystitis).

• Heart rate: In the phase 2 trial, heart rates rose with higher doses, peaked around week 24, then eased off. The glucagon-driven heart rate bump is unique to retatrutide and may matter more in patients with increased cardiac risk.

For clinicians, these topline results suggest that the highest-efficacy dose isn’t automatically the right target for every patient. Dose selection may end up being more individualized than with current incretin mimetics.

4. Safety and side effects

Across phase 2 and phase 3, the most common side effects of retatrutide were gastrointestinal in nature — nausea, vomiting, diarrhea, and constipation — similar to those of other agents in this class. They were dose-dependent and clustered around each dose step-up. Slow titration is the single biggest factor separating patients who tolerate the drug from those who quit.

Two effects are specific to retatrutide though:

• Heart rate: Resting heart rate rose by roughly 5 bpm to 11 bpm in a phase 2 trial. This was a dose-dependent effect with higher heart rates at higher doses peaking around week 24 before declining again. A baseline and periodic heart rate check makes sense for patients with arrhythmias or significant cardiac risk.

• Dysesthesia: Some patients report skin tingling, burning, or hypersensitivity. It was uncommon (about 7%) but showed up more often at the top dose. It appears to be reversible after stopping the medication.

5. The grey market

The grey market is a real counseling issue with patients, who may be asking about peptides for weight loss. Because the buzz has outpaced approval, unregulated “retatrutide peptide” products are sold online as “research chemicals.” These products are not the trialed drug. They’re of unknown purity and dose and may contain broken-down peptides or contaminants. 

The FDA has sent warning letters to sellers and has made clear that retatrutide can’t be legally compounded, since it isn’t part of an approved product. The FDA specifically asks clinicians to talk with patients about the risks of these products.

6. The approval timeline

As of mid-2026, retatrutide is still investigational and the manufacturer hasn’t yet filed a New Drug Application. Three phase 3 trials have now reported positive results with several more expected through the rest of 2026 (more on this below). Obesity is the likeliest first indication, since it has the strongest data behind it.

Eli Lilly is expected to submit an application in late 2026 or early 2027. The FDA’s standard review runs about 10 months after that, which puts a realistic approval window in late 2027 to 2028. 

7. Other indications under investigation

Retatrutide is being studied in several other conditions where its metabolic effects might help. Most of this work is still in progress, with results years away:

• Type 2 diabetes: The first trial to report, which included patients not yet on diabetes medication, showed strong results, with A1C levels dropping by roughly 2%.

• Knee osteoarthritis: In adults with obesity and knee osteoarthritis, the drug cut knee pain by up to roughly 76%, and more than 1 in 8 patients reported complete resolution of knee pain.

• Heart and kidney: A large outcomes trial is testing whether retatrutide lowers the risk of major adverse cardiovascular events and slows chronic kidney disease. Early phase 2 data hinted at improved kidney function, but the definitive results aren’t expected until around 2029.

• Obstructive sleep apnea: Trials are tracking whether retatrutide improves obstructive sleep apnea (OSA), building on evidence that GLP-1 drugs can help. For now, tirzepatide is the only incretin mimetic FDA approved for OSA.

• Metabolic dysfunction-associated steatotic liver disease (MASLD): In an early trial, retatrutide produced large reductions in liver fat, with most patients on the highest dose reaching a normal level. A phase 3 outcomes trial is underway but won’t finish until the early 2030s.

• Chronic low back pain: A trial is testing whether retatrutide eases chronic low back pain in adults with obesity — part of broader interest in whether these drugs have a role in chronic pain. Results are expected in 2027.

Why trust our experts?

Written by:

Farzon A. Nahvi, MD

Farzon Nahvi, MD, is an emergency medicine physician and author of “Code Gray: Death, Life, and Uncertainty in the ER.” He works at Concord Hospital in Concord, New Hampshire, and teaches at the Geisel School of Medicine at Dartmouth.

Edited by:

Mandy Armitage, MD

Mandy Armitage, MD, has combined clinical medicine with her passion for education and content development for many years. She is co-executive director at Nonclinical Physicians Network and has served as medical director for the health technology companies HealthLoop (now Get Well) and Doximity.

Reviewed by:

Farah Naz Khan, MD

Farah Naz Khan, MD, is a board-certified physician at the UW Medicine Diabetes Institute and a clinical assistant professor of metabolism, endocrinology, and nutrition at the University of Washington.

Our editorial standards

Meet our experts